|
| Status |
Public on Feb 27, 2018 |
| Title |
Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Interactions between a new potent Bromodomain and extraterminal domain (BET) inhibitor BI 894999 and the polo-like kinase (PLK) inhibitor volasertib were studied in acute myeloid leukemia cell lines in vitro and in vivo. We provide data for the distinct mechanisms of action of these two compounds with a potential utility in AML based on gene expression, cell cycle profile and modulation of PD biomarkers such as MYC and HEXIM1. In contrast to BI 894999, volasertib treatment neither affects MYC nor HEXIM1 expression, but augments and prolongs the decrease of MYC expression caused by BI 894999 treatment. In vitro combination of both compounds leads to a decrease in S-Phase and to increased apoptosis. In vitro scheduling experiments guided in vivo experiments in disseminated AML mouse models. Co-administration of BI 894999 and volasertib dramatically reduces tumor burden accompanied by long-term survival of tumor-bearing mice and eradication of AML cells in mouse bone marrow. Together, these preclinical findings provide evidence for the strong synergistic effect of BI 894999 and volasertib, warranting future clinical studies in patients with AML to investigate this paradigm.
|
| |
|
| Overall design |
MV-4-11B cells were treated with either BI 894999 (1 nM or 35 nM) or volasertib (20 nM) or the combination of both for 4h or 24h. Subsequently cells were harvested for total RNA isolation using TriZol (Ambion) and further purified using miRNAeasy columns (Qiagen). Approximately 500ng of total RNA were subjected to library preparation using the TruSeq RNA Library Prep Kit v2 with polyA selection as recommended by the manufacturer (Illumina) without generating stranded information. Library were multiplexed and sequenced on a HiSeq1500 using paired-end sequencing with 50 cycles each.
|
| Web link |
https://doi.org/10.1016/j.canlet.2018.02.018
|
| |
|
| Contributor(s) |
Tontsch-Grunt U, Gerlach D, Savarese F, Schweifer N, Kaya O |
| Citation(s) |
29454094 |
| |
| Submission date |
Aug 24, 2017 |
| Last update date |
May 15, 2019 |
| Contact name |
Daniel Gerlach |
| E-mail(s) |
daniel.gerlach@boehringer-ingelheim.com
|
| Organization name |
Boehringer Ingelheim RCV GmbH & Co KG
|
| Department |
Global Computational Biology and Digital Sciences
|
| Street address |
Dr.-Boehringer-Gasse 5-11
|
| City |
Vienna |
| ZIP/Postal code |
1121 |
| Country |
Austria |
| |
|
| Platforms (1) |
| GPL18460 |
Illumina HiSeq 1500 (Homo sapiens) |
|
| Samples (36)
|
|
| Relations |
| BioProject |
PRJNA400080 |
| SRA |
SRP116140 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE103068_BI00894999_1nM_Volasertib_20nM_vs_DMSO_24h_dge.tsv.gz |
2.8 Mb |
(ftp)(http) |
TSV |
| GSE103068_BI00894999_1nM_Volasertib_20nM_vs_DMSO_4h_dge.tsv.gz |
2.8 Mb |
(ftp)(http) |
TSV |
| GSE103068_BI00894999_1nM_vs_DMSO_24h_dge.tsv.gz |
2.8 Mb |
(ftp)(http) |
TSV |
| GSE103068_BI00894999_1nM_vs_DMSO_4h_dge.tsv.gz |
2.9 Mb |
(ftp)(http) |
TSV |
| GSE103068_BI00894999_35nM_Volasertib_20nM_vs_DMSO_24h_dge.tsv.gz |
2.8 Mb |
(ftp)(http) |
TSV |
| GSE103068_BI00894999_35nM_Volasertib_20nM_vs_DMSO_4h_dge.tsv.gz |
2.9 Mb |
(ftp)(http) |
TSV |
| GSE103068_BI00894999_35nM_vs_DMSO_24h_dge.tsv.gz |
2.8 Mb |
(ftp)(http) |
TSV |
| GSE103068_BI00894999_35nM_vs_DMSO_4h_dge.tsv.gz |
2.9 Mb |
(ftp)(http) |
TSV |
| GSE103068_Volasertib_20nM_vs_DMSO_24h_dge.tsv.gz |
2.8 Mb |
(ftp)(http) |
TSV |
| GSE103068_Volasertib_20nM_vs_DMSO_4h_dge.tsv.gz |
2.8 Mb |
(ftp)(http) |
TSV |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data are available on Series record |
Less...
More...